Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Titan Pharmaceuticals has reported that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile.
Subscribe to our email newsletter
The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24mg/day, ziprasidone at 160mg/day or placebo. Patients treated with iloperidone had significantly greater improvements in positive and negative syndrome scale-total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.
Iloperidone and ziprasidone showed similarly low effects on glucose, cholesterol, triglyceride and prolactin levels compared to placebo, and iloperidone was also associated with a favorable profile on the extrapyramidal symptoms rating scale (ESRS) versus placebo.